WallStreetZenWallStreetZen

NASDAQ: CBIO
Crescent Biopharma Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Should I buy or sell CBIO stock?

Based on 1 analyst offering ratings for Crescent Biopharma Inc.

Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model agrees with analyst consensus with a "Hold" rating. Learn More

Be the first to know when Wall Street analysts revise their CBIO stock forecasts and price targets.

CBIO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-06-01

1 of 1

Forecast return on equity

Is CBIO forecast to generate an efficient return?

Company
-87.72%
Industry
74.63%
Market
169.95%
CBIO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CBIO forecast to generate an efficient return on assets?

Company
-78.36%
Industry
38.34%
CBIO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CBIO earnings per share forecast

What is CBIO's earnings per share in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
-$3.24
Avg 2 year Forecast
-$3.43
Avg 3 year Forecast
-$3.77

CBIO revenue forecast

What is CBIO's revenue in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
$2.0M-81.59%
Avg 2 year Forecast
$4.9M-54.99%
Avg 3 year Forecast
$7.0M-35.72%
CBIO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CBIO revenue growth forecast

How is CBIO forecast to perform vs Biotechnology companies and vs the US market?

Company
-13.09%
Industry
32.52%
Market
13.49%
CBIO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CBIO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CBIO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CBIO$16.43N/AN/AHold
SPRY$6.05$27.00+346.28%Strong Buy
FDMT$11.87$31.00+161.16%Strong Buy
MDXG$4.28$7.00+63.55%Strong Buy
HELP$11.49$34.00+195.91%Strong Buy
View Top Biotech Stocks

Crescent Biopharma Stock Forecast FAQ

Is Crescent Biopharma Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: CBIO) stock is to Hold CBIO stock.

Out of 1 analyst, 0 (0%) are recommending CBIO as a Strong Buy, 0 (0%) are recommending CBIO as a Buy, 1 (100%) are recommending CBIO as a Hold, 0 (0%) are recommending CBIO as a Sell, and 0 (0%) are recommending CBIO as a Strong Sell.

If you're new to stock investing, here's how to buy Crescent Biopharma stock.

What is CBIO's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: CBIO) Crescent Biopharma's current Earnings Per Share (EPS) is -$7.63. On average, analysts forecast that CBIO's EPS will be -$3.24 for 2026, with the lowest EPS forecast at -$3.37, and the highest EPS forecast at -$3.06. On average, analysts forecast that CBIO's EPS will be -$3.43 for 2027, with the lowest EPS forecast at -$4.62, and the highest EPS forecast at -$2.63. In 2028, CBIO's EPS is forecast to hit -$3.77 (min: -$4.41, max: -$3.05).

What is CBIO's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: CBIO) forecast ROE is -87.72%, which is considered weak.

What is CBIO's earnings growth forecast for 2026-2028?

(NASDAQ: CBIO) Crescent Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.83%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.85%.

Crescent Biopharma's earnings in 2026 is -$165,124,000.On average, 10 Wall Street analysts forecast CBIO's earnings for 2026 to be -$120,383,510, with the lowest CBIO earnings forecast at -$125,219,651, and the highest CBIO earnings forecast at -$113,493,309. On average, 10 Wall Street analysts forecast CBIO's earnings for 2027 to be -$127,370,285, with the lowest CBIO earnings forecast at -$171,448,998, and the highest CBIO earnings forecast at -$97,502,843.

In 2028, CBIO is forecast to generate -$139,898,936 in earnings, with the lowest earnings forecast at -$163,804,775 and the highest earnings forecast at -$113,103,297.

What is CBIO's revenue growth forecast for 2026-2028?

(NASDAQ: CBIO) Crescent Biopharma's forecast annual revenue growth rate of -13.09% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.49%.

Crescent Biopharma's revenue in 2026 is $10,844,000.On average, 10 Wall Street analysts forecast CBIO's revenue for 2026 to be $74,139,304, with the lowest CBIO revenue forecast at $36,401,061, and the highest CBIO revenue forecast at $333,069,710. On average, 9 Wall Street analysts forecast CBIO's revenue for 2027 to be $181,299,571, with the lowest CBIO revenue forecast at $0, and the highest CBIO revenue forecast at $877,525,583.

In 2028, CBIO is forecast to generate $258,893,262 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $1,170,034,110.

What is CBIO's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: CBIO) forecast ROA is -78.36%, which is lower than the forecast US Biotechnology industry average of 38.34%.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.